News | October 14, 2014

New Targeted Radiosurgery Technology Provides Highly Accurate Treatment, Greater Patient Comfort

Henry Ford Hospital Detroit Varian Medical Systems Edge Radiosurgery Suite

Henry Ford Hospital in Detroit was the first in North America and the only hospital in Michigan to have the Edge Radiosurgery Suite.

October 14, 2014 — A new stereotactic radiosurgery system provides the same or a higher level of accuracy in targeting cancer tumors — but offers greater comfort to patients and the ability to treat multiple tumors at once — when compared to other radiation therapy stereotactic systems, according to researchers at Henry Ford Hospital in Detroit.

The study shows the Edge Radiosurgery Suite is able to target cancer tumors within 1 mm, providing sub-millimeter accuracy with extreme precision.

“Radiosurgery is just one shot of precision radiation with a very high dose to treat tumors,” says study lead author Ning Wen, Ph.D., a physicist with the department of radiation oncology at Henry Ford.

“The key is targeting the tumor and delivering the dose that we want while protecting surrounding normal tissue, which is why it is so important to regularly evaluate the systematic accuracy of such systems.”

The study as presented at the 56th annual American Society for Radiation Oncology (ASTRO) meeting in San Francisco.

Stereotactic radiation is a procedure that precisely delivers intense radiation doses to tumor targets in one to five treatments. The goal of this non-invasive procedure is to destroy, or make inactive, the tumor while minimizing dose exposure to the surrounding healthy tissue.

The Edge, created by Varian Medical Systems, is the latest advancement in stereotactic radiosurgery. It offers treatment in about 20 minutes and uses new real-time tumor tracking technology to help compensate for tumor motion during treatment. Its six degrees of freedom treatment couch provides flexibility needed to optimally position and adjust patients, allowing them to be comfortable and breathe freely during treatment.

Henry Ford was the first in North America and it is the only hospital in Michigan to have the Edge.

“The Edge truly represents a novel platform in radiosurgery, offering a system that provides a fully-integrated solution for planning and administering radiosurgery treatments,” notes Benjamin Movsas, M.D., chair of the department of radiation oncology at Henry Ford and a co-author of the study.

For its study, Henry Ford sought to evaluate the accuracy of the Edge by comparing it to existing robot- or frame-based radiosurgery systems.

To do so, researchers took a novel approach using — for the first time — a phantom prototype cube to determine treatment precision.

The phantom includes implanted inserts and has four different densities for cone beam computed tomography, three Calypso beacons, 5 mm diameter steel BBs in the center for localization accuracy testing, 16 ceramic BBs for radiographic imaging, and simultaneous dual orthogonal film planes insert for dosimetric verification.

With the phantom prototype, targets were localized using all components of the Edge system, including optical surface monitoring system, electromagnetic beacon-based tracking, cone-beam computed tomography (CT), “snap-shot” planar x-ray imaging during treatment and a “robotic” six-degree of freedom couch.

Ten plans were created to study various treatment sites including brain, spine, lung and pancreas.

Overall, the study demonstrated that the “end-to-end” locational accuracy of the Edge was within 0.9 mm for single target treatment and 1.2 mm for single isocenter multi-targets treatment, making it highly accurate when compared to robot- or frame-based radiosurgery systems.

“With our radiosurgery team, everything we do is continuously under study,” says Wen. “As pioneers in the field, we want to show we have done due diligence with this new system to ensure we’re providing the best care to our patients.”

Wen and his colleagues plan to continue to study the Edge, expanding their research to evaluation how tumors interact with treatment.

Along with Drs. Wen and Movsas, Henry Ford study co-authors are Haisen Li, Ph.D.; Kang Song, Karen Chin Snyder, Jinkoo Kim, Hualiang Zhong, James Gordon, Ph.D.; Indrin Chetty, Ph.D.; Salim Siddiqui, M.D.; Farzan Siddiqui, M.D.; Munther Ajlouni, M.D.; and Samuel Ryu, M.D.

Research support for this study was provided by Varian and Henry Ford Hospital.

For more information: www.henryford.com

Related Content

Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Clinical Trials and Cutting-Edge Radiation Oncology Research to Be Featured at ASTRO 2017
News | Radiation Therapy | September 14, 2017
The program for the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San...
Provision Healthcare Joins RayCare Clinical Partners
News | Oncology Information Management Systems (OIMS) | September 11, 2017
Provision, located in Knoxville, Tenn., is the latest to partner with RaySearch Laboratories on the development of its...
U.K.'s NICE Supports Use of Hydrogel Spacer in Prostate Cancer Treatement
News | Patient Positioning Radiation Therapy | September 08, 2017
Augmenix Inc. announced that the National Institute for Health and Care Excellence (NICE) in the U.K. has issued...
Sponsored Content | Videos | Radiation Therapy | September 08, 2017
The new Visicoil MR is a helically-wound, flexible linear fiducial marker.
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Augmenix Announces Medicare Administrative Contractor Palmetto Coverage for SpaceOAR Hydrogel
News | Patient Positioning Radiation Therapy | September 05, 2017
Augmenix Inc. announced that Palmetto GBA LLC — the Medicare Administrative Contractor (MAC) covering North Carolina,...
Penn Medicine to Host Fourth Annual Proton Therapy Training Course
News | Proton Therapy | August 30, 2017
August 30, 2017 — IBA (Ion Beam Applications S.A.) and the Department of Radiation Oncology at Penn Medicine, in part
Overlay Init